<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221036</url>
  </required_header>
  <id_info>
    <org_study_id>Vedolizumab-3033</org_study_id>
    <secondary_id>U1111-1195-3994</secondary_id>
    <nct_id>NCT03221036</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction&#xD;
      and maintenance treatment in Chinese participants with moderately to severely active&#xD;
      ulcerative colitis (UC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Vedolizumab. Vedolizumab will be administered&#xD;
      as an intravenous (IV) infusion. This study will investigate the efficacy and safety of&#xD;
      vedolizumab IV as induction and maintenance therapy in participants with moderately to&#xD;
      severely active ulcerative colitis (UC).&#xD;
&#xD;
      The study will enroll approximately 302 moderately to severely active patients with&#xD;
      ulcerative colitis.&#xD;
&#xD;
      The Induction Phase contained 2 cohorts of participants: Cohort 1 participants will be&#xD;
      randomized 1:2 in a double-blinded manner to receive:&#xD;
&#xD;
        -  Vedolizumab IV 300 mg&#xD;
&#xD;
        -  Placebo IV&#xD;
&#xD;
      Cohort 2 participants will be treated with open-label vedolizumab. The second cohort was&#xD;
      enrolled to ensure that the sample size of Induction Phase responders randomized into the&#xD;
      Maintenance Study provided sufficient power for the Maintenance Study primary efficacy&#xD;
      analysis.&#xD;
&#xD;
      Participants will receive induction therapy of Vedolizumab 300 mg or matching placebo,&#xD;
      intravenous (IV) infusion at Weeks 0, 2, and 6. At Week 10, participants will be assessed for&#xD;
      clinical response based on complete clinic Mayo score. Results of Week 10 clinical response&#xD;
      will determine the treatment pathway in maintenance phase.&#xD;
&#xD;
      In the Maintenance Phase, participants who received vedolizumab in the induction phase and&#xD;
      achieved clinical response at Week 10 will be randomized 1:1 in a double-blinded manner to&#xD;
      receive vedolizumab IV 300 mg or placebo starting from Week 14 (i.e., Weeks 14, 22, 30, 38,&#xD;
      46, and 54).&#xD;
&#xD;
      This multi-center trial will be conducted in China. The overall time to participate in this&#xD;
      study is 60 weeks. Participants will make multiple visits to the clinic, and will be&#xD;
      contacted by telephone, 6 months after last dose of study drug for a long term follow-up&#xD;
      safety survey.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">October 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Clinical Response at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Clinical response is defined as ≥3 points reduction in complete Mayo clinical score and ≥30% decrease from baseline score accompanied with ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding subscore ≤1. Mayo clinical score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Clinical Remission at Week 60</measure>
    <time_frame>Week 60</time_frame>
    <description>Clinical remission is defined as complete Mayo clinic score ≤2 with no subscore &gt;1. Mayo clinic score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Clinical remission is defined as complete Mayo clinic score ≤2 with no subscore &gt;1. Mayo clinic score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Mucosal Healing at Weeks 10 and 60</measure>
    <time_frame>Weeks 10 and 60</time_frame>
    <description>Mucosal healing is defined as Mayo endoscopic subscore ≤1. Mayo clinic score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Durable Clinical Response at Weeks 10 and 60</measure>
    <time_frame>Weeks 10 and 60</time_frame>
    <description>Clinical response is defined as ≥3 points reduction in complete Mayo clinical score and ≥30% decrease from baseline score accompanied with ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding subscore ≤1. Mayo clinic score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Durable Clinical Remission at Weeks 10 and 60</measure>
    <time_frame>Weeks 10 and 60</time_frame>
    <description>Clinical remission is defined as complete Mayo clinic score ≤2 with no subscore &gt;1. Mayo clinic score is used to assess ulcerative colitis disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo clinic score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Oral Corticosteroids at Baseline who have Discontinued Corticosteroids and are in Clinical Remission at Week 60</measure>
    <time_frame>Week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">302</enrollment>
  <condition>Moderately to Severely Active Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Induction Phase: Vedolizumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: Vedolizumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab IV</intervention_name>
    <description>Vedolizumab IV infusion</description>
    <arm_group_label>Induction Phase: Vedolizumab 300 mg</arm_group_label>
    <arm_group_label>Maintenance Phase: Vedolizumab 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching-placebo IV infusion</description>
    <arm_group_label>Induction Phase: Placebo</arm_group_label>
    <arm_group_label>Maintenance Phase: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has a diagnosis of ulcerative colitis (UC) established at least 3 months prior to&#xD;
             Screening by clinical and endoscopic evidence corroborated by a histopathology report.&#xD;
&#xD;
          2. Has moderately to severely active UC as determined by a complete Mayo score of 6-12&#xD;
             with an endoscopic subscore ≥2 within 10 days prior to the first dose of study drug.&#xD;
             The endoscopy can be performed during the Screening Phase (Day -10 to Day -5 to allow&#xD;
             for central reading prior to first dose at Week 0).&#xD;
&#xD;
          3. Has evidence of UC extending proximal to the rectum (≥15 cm of involved colon).&#xD;
&#xD;
          4. Participants with extensive colitis or pancolitis of &gt;8 years duration or left-sided&#xD;
             colitis &gt;12 years duration must have documented evidence that a surveillance&#xD;
             colonoscopy was performed within 12 months of the initial Screening Visit (may be&#xD;
             performed during screening).&#xD;
&#xD;
          5. Participants with a family history of colorectal cancer, personal history of increased&#xD;
             colorectal cancer risk, age &gt;50 years, or other known risk factors must be up-to-date&#xD;
             on colorectal cancer surveillance (may be performed during screening).&#xD;
&#xD;
          6. Has demonstrated an inadequate response to, loss of response to, or intolerance of at&#xD;
             least 1 of the following agents: corticosteroids, immunomodulators, or tumor necrosis&#xD;
             factor alpha (TNF-α) antagonists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.&#xD;
&#xD;
          2. Has had extensive colonic resection, subtotal or total colectomy.&#xD;
&#xD;
          3. Has an existing ileostomy, colostomy, or known fixed symptomatic stenosis of the&#xD;
             intestine. A history of ileostomy or colostomy that has been reversed may be&#xD;
             acceptable.&#xD;
&#xD;
          4. Has had any previous exposure to approved or investigational anti-integrins (e.g.,&#xD;
             natalizumab, efalizumab, etrolizumab, or AMG-181) or mucosal addressin cell adhesion&#xD;
             molecule-1 (MAdCAM-1) antagonist, or rituximab.&#xD;
&#xD;
          5. Has used a topical (rectal) treatment with 5-acetyl salicylic acid (5-ASA) or&#xD;
             corticosteroid enemas/suppositories or traditional Chinese medications for treatment&#xD;
             of UC within 2 weeks of the administration of the first dose of study drug.&#xD;
&#xD;
          6. Currently requires or is anticipated to require surgical intervention for UC during&#xD;
             the study.&#xD;
&#xD;
          7. Has a history or evidence of adenomatous colonic polyps that have not been removed, or&#xD;
             has a history or evidence of colonic mucosal dysplasia including low or high-grade&#xD;
             dysplasia, as well as indeterminate for dysplasia.&#xD;
&#xD;
          8. Has a suspected or confirmed diagnosis of Crohn's enterocolitis, indeterminate&#xD;
             colitis, ischemic colitis, radiation colitis, diverticular disease associated with&#xD;
             colitis, or microscopic colitis.&#xD;
&#xD;
          9. Has evidence of or has had treatment for C. difficile infection or other intestinal&#xD;
             pathogen within 28 days prior to randomization.&#xD;
&#xD;
         10. Has chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV)&#xD;
             infection.&#xD;
&#xD;
         11. Has active or latent TB.&#xD;
&#xD;
         12. Has any identified congenital or acquired immunodeficiency (e.g., common variable&#xD;
             immunodeficiency, human immunodeficiency virus [HIV] infection, organ&#xD;
             transplantation).&#xD;
&#xD;
         13. Has any history of malignancy, except for the following: (a) adequately treated&#xD;
             non-metastatic basal cell skin cancer; (b) squamous cell skin cancer that has been&#xD;
             adequately treated and that has not recurred for at least 1 year prior to&#xD;
             randomization; and (c) history of cervical carcinoma in situ that has been adequately&#xD;
             treated and that has not recurred for at least 3 years prior to randomization.&#xD;
             Subjects with remote history of malignancy (eg, &gt;10 years since completion of curative&#xD;
             therapy without recurrence) will be considered based on the nature of the malignancy&#xD;
             and the therapy received and must be discussed with the sponsor on a case-by-case&#xD;
             basis prior to randomization.&#xD;
&#xD;
         14. Has a history of any major neurological disorders, including stroke, multiple&#xD;
             sclerosis, brain tumor, or neurodegenerative disease.&#xD;
&#xD;
         15. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom&#xD;
             checklist at Screening or prior to the administration of the first dose of study drug&#xD;
             at Week 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613956038063</phone>
      <email>hnz1956@msn.com</email>
    </contact>
    <investigator>
      <last_name>Naizhong Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613910702345</phone>
      <email>wuyongdong@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yongdong Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8610110325</phone>
      <email>hongy72@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613883032812</phone>
      <email>chendf1981@163.com</email>
    </contact>
    <investigator>
      <last_name>Dongfeng Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613860628134</phone>
      <email>wangwen1386@163.com</email>
    </contact>
    <investigator>
      <last_name>Wen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613806019655</phone>
      <email>wl720807@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Zhangzhou</city>
        <state>Fujian</state>
        <zip>363000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613055964918</phone>
      <email>lyd0596@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yadong Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613802791808</phone>
      <email>wh-sha@163.com</email>
    </contact>
    <investigator>
      <last_name>Weihong Sha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613802957089</phone>
      <email>chenminhu@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Minhu Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>86 10 80705506</phone>
      <email>liuside@163.com</email>
    </contact>
    <investigator>
      <last_name>Side Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13502405878</phone>
      <email>helen_gao818@163.com; Helengao818@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiang Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613035143646</phone>
      <email>houxh@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaohua Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613971107769</phone>
      <email>tiandeanwh@163.com</email>
    </contact>
    <investigator>
      <last_name>Dean Tian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613098803507</phone>
      <email>812328105@qq.com</email>
    </contact>
    <investigator>
      <last_name>Shiyun Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613787270539</phone>
      <email>meihuaxu2001@163.com</email>
    </contact>
    <investigator>
      <last_name>Meihua Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613974812392</phone>
      <email>liudeliang1964@163.com</email>
    </contact>
    <investigator>
      <last_name>Deliang Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613975198393</phone>
      <email>ssr-35403@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoyan Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613770771661</phone>
      <email>zouxiaoping795@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoping Zou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613951913128</phone>
      <email>guoxinz@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Guoxin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>241023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613358110715</phone>
      <email>xmzb1013@163.com</email>
    </contact>
    <investigator>
      <last_name>Min Xia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613970090801</phone>
      <email>jyyfyzx@163.com</email>
    </contact>
    <investigator>
      <last_name>Xuan Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613756661648</phone>
      <email>chxuhong@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8618940251666</phone>
      <email>zhengchangqing88@163.com</email>
    </contact>
    <investigator>
      <last_name>Changqing Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613995218678</phone>
      <email>shaoqiynh@163.com</email>
    </contact>
    <investigator>
      <last_name>Shaoqi Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613817815616</phone>
      <email>jimmyzj64@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jie Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613817783888</phone>
      <email>shen.xizhong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Xizhong Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8618917683431</phone>
      <email>liuzhanju88@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhanju Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613818868519</phone>
      <email>13818868519@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiangao Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8618980601283</phone>
      <email>wangyufang04@126.com</email>
    </contact>
    <investigator>
      <last_name>yufang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613708498467</phone>
      <email>1269810285@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yinglei Miao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8613757118653</phone>
      <email>chenyan@cccf4u.com</email>
    </contact>
    <investigator>
      <last_name>Yan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>8657186006642</phone>
      <email>caoq@srrsh.com</email>
    </contact>
    <investigator>
      <last_name>Qian Cao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

